Skip to main
NGNE
NGNE logo

Neurogene Inc (NGNE) Stock Forecast & Price Target

Neurogene Inc (NGNE) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Neurogene Inc. has garnered increased confidence in its lead candidate, NGN-401, for the treatment of Rett syndrome, particularly due to improvements in monitoring and management of potential HLH reactions. The advancement of its proprietary EXACT platform is being validated by positive observations of intracerebroventricular (ICV) advantages, suggesting a solid and reproducible clinical relevance that enhances the outlook for future trials. Furthermore, with expectations of expedited trial enrollment and the possibility of demonstrating significant clinical benefits, there is a heightened optimism regarding Neurogene's ability to conduct a successful pivotal trial for its candidates.

Bears say

Neurogene Inc faces significant financial challenges stemming from the potential clinical failures of key drug candidates, particularly NGN-401 for Rett syndrome, which could severely hinder the company's ability to raise necessary capital. Furthermore, there are considerable risks associated with delays in clinical trial advancement and the possibility of unfavorable clinical outcomes, which may deteriorate investor confidence. Additionally, external factors such as negative investor sentiment regarding drug pricing, mergers and acquisitions, and sector valuations could adversely affect the company's market valuation and overall financial stability.

Neurogene Inc (NGNE) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neurogene Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neurogene Inc (NGNE) Forecast

Analysts have given Neurogene Inc (NGNE) a Buy based on their latest research and market trends.

According to 4 analysts, Neurogene Inc (NGNE) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neurogene Inc (NGNE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.